Detailed information for compound 923399

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 598.005 | Formula: C32H35Cl3N4O
  • H donors: 2 H acceptors: 2 LogP: 8.99 Rotable bonds: 15
    Rule of 5 violations (Lipinski): 2
  • SMILES: Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NCCCCCCCCNCc1ccccc1
  • InChi: 1S/C32H35Cl3N4O/c1-23-30(32(40)37-20-10-5-3-2-4-9-19-36-22-24-11-7-6-8-12-24)38-39(29-18-17-27(34)21-28(29)35)31(23)25-13-15-26(33)16-14-25/h6-8,11-18,21,36H,2-5,9-10,19-20,22H2,1H3,(H,37,40)
  • InChiKey: ONBPONFRDDTIII-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cannabinoid receptor 1 (brain) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi Dihydrofolate reductase 0.7981 1 1
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.4592 0.498 0.5
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.7981 1 1
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.4592 0.498 0.5
Leishmania major dihydrofolate reductase-thymidylate synthase 0.4592 0.498 0.5
Echinococcus granulosus dihydrofolate reductase 0.7981 1 1
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.4592 0.498 0.5
Loa Loa (eye worm) dihydrofolate reductase 0.7981 1 1
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.7981 1 1
Echinococcus multilocularis dihydrofolate reductase 0.7981 1 1
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 0.4592 0.498 0.5
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 0.4592 0.498 0.5
Onchocerca volvulus 0.1231 0 0.5
Schistosoma mansoni dihydrofolate reductase 0.7981 1 1
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.7981 1 1
Chlamydia trachomatis dihydrofolate reductase 0.7981 1 0.5

Activities

Activity type Activity value Assay description Source Reference
EC50 (binding) = 6.91 Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP after 20 mins by steady-state GTPase assay ChEMBL. 25096297
EC50 (binding) = 0.123 uM Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP after 20 mins by steady-state GTPase assay ChEMBL. 25096297
Emax (binding) = 93.77 % Inverse agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP at 30 uM after 20 mins by steady-state GTPase assay relative to control ChEMBL. 25096297
Inhibition (binding) = 93.9 % Displacement of [3H] CP-55,940 from human CB2 receptor expressed in HEK cells at 10 uM after 3 hrs by scintillation counting ChEMBL. 25096297
Ki (binding) = 31 uM Displacement of [3H] CP-55,940 from human CB2 receptor expressed in HEK cells at 10 uM after 3 hrs by scintillation counting ChEMBL. 25096297

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.